Radiologic findings from a closely watched trial of glatiramer acetate (Copaxone) and interferon-beta-1a (Avonex) combination therapy in relapsing remitting multiple sclerosis were mixed, a researcher said here.
Compared with the individual drugs given alone for 3 years, the combination was superior in terms of new lesion activity visible on MRI scans and in the accumulation of total lesion volumes, said Jerry Wolinsky, MD, of the University of Texas Health Science Center in Houston.
But the combination failed to show an advantage over monotherapy in several other key radiological measures, including brain atrophy, volume of normal-appearing grey and white matter, and the so-called Z4 composite score, Wolinsky told attendees at the American Academy of Neurology meeting.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1767